Oil slips after Libya resumes output, China data eyed Oil prices dipped for a second session on Monday after Libya resumed production over the weekend while China, the world’s largest crude importer, is expected to release economic data showing that its post-pandemic recovery is fizzling out. Brent crude futures fell 57 cents, or 0.7%, to $79.30 a barrel by 0055 GMT while U.S. West Texas Intermediate crude was at $74.90 a barrel, down 52 cents, or 0.7%. Two of the three Libyan oilfields shut on Thursday, the Sharara and El Feel oilfields with a total production capacity of 370,000 barrels per day (bpd), resumed on Saturday evening, four oil engineers and oil ministry said. The 108 field remained shut. Output was halted in protest against the abduction of a former finance minister. In Russia, oil exports from western ports are set to fall by some 100,000-200,000 bpd next month from July levels, a sign Moscow is making good on its pledge for fresh supply cuts in tandem with OPEC leader Saudi Arabia, two sources said on Friday, citing export plans. On the economic front, stronger-than-expected consumer sentiment data in the U.S. on Friday dampened expectations that the Federal Reserve was set to end its rate hiking cycle at next week’s Federal Open Market Committee (FOMC) meeting, IG analyst Tony Sycamore said. There is also some nervousness among traders ahead of another big week ahead for economic data from China, the UK and Japan, he added. “All three of these readings will play a part in determining what the next move is for three key central banks the PBOC, BoE and the BoJ and by extension whether oil demand will receive a boost,” Sycamore said.
Also Read: Zerodha’s Nikhil Kamath tells when to buy stocks, shares Buffett formula to find the right time
FII and DII trades: Foreign Institutional Investors (FII) have been net buyers of domestic stocks for successive days now. On Wednesday, FIIs pumped in Rs 2,347 crore. Domestic Institutional Investors (DII) have been net sellers, pulling out Rs 510 crore yesterday.
IPO watch: Syrma SGS Technology enters the final day of bidding today. So far the issue, that opened last week, has been subscribed 2.27 times. Retail investors have subscribed their portion 2.66 times while NIIs have bid for their quota 3.58 times and QIB portion has been bid for 0.71 times.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.